Immuneering Q3 loss widens beyond expectations on R&D spending
IMRX•Immuneering reported a Q3 net loss of $24.20 million, or $0.37 per share, missing analyst expectations of $20.74 million and $0.31 per share. The company expects its cash runway to fund operations into Q4 2028.
1. Quarterly results
Immuneering’s Q3 net loss widened beyond analyst expectations as higher research and development expenses, mainly from increased clinical costs and added personnel, drove losses. The company reported a net loss of $24.20 million and a loss of $0.37 per share, compared with estimates of $20.74 million and $0.31 per share.
2. Clinical outlook
Immuneering expects updated Phase 2 pancreatic cancer data in the first half of 2027. Enrollment in its Phase 3 MAPKeeper 301 trial is ahead of schedule, and the company now expects topline data in mid-2028. It expects its cash runway to fund operations into Q4 2028.
